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GWAS of bone size yields twelve loci that also
affect height, BMD, osteoarthritis or fractures
Unnur Styrkarsdottir
Bone area is one measure of bone size that is easily derived from dual-energy X-ray
absorptiometry (DXA) scans. In a GWA study of DXA bone area of the hip and lumbar spine
(N≥ 28,954), we ﬁnd thirteen independent association signals at twelve loci that replicate in
samples of European and East Asian descent (N= 13,608 – 21,277). Eight DXA area loci
associate with osteoarthritis, including rs143384 in GDF5 and a missense variant in COL11A1
(rs3753841). The strongest DXA area association is with rs11614913[T] in the microRNA
MIR196A2 gene that associates with lumbar spine area (P= 2.3 × 10−42, β=−0.090) and
confers risk of hip fracture (P= 1.0 × 10−8, OR= 1.11). We demonstrate that the risk allele is
less efﬁcient in repressing miR-196a-5p target genes. We also show that the DXA area
measure contributes to the risk of hip fracture independent of bone density.
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Human height and other characteristics of the body’s sizeand shape have been extensively studied in large genomewide association (GWA) studies, yielding many associated
loci1–8. Studies of parameters of body composition, such as lean
mass, fat mass, and bone mineral density (BMD) have also yiel-
ded a number of associated loci9–19. An important component of
human height and body form is the size and shape of the bones.
Not only is height directly related to bone size but the size and
shape of bones may contribute to their strength and risk of
fracture20, and the tendency to develop osteoarthritis21,22. DXA
scans are primarily performed to evaluate BMD and fracture risk.
The scans assess the area (cm2) and the bone mineral content
(BMC, g) of the bone, to produce the BMD (g/cm2). BMD from
DXA scans has found over 100 loci in many GWA studies11–17,
and estimated BMD from quantitative ultrasound of the heel over
1000 independent associations in the large UK Biobank
resource18,19. The few GWA studies of bone area of the hip or
lumbar spine using DXA have not yielded signiﬁcant loci23–27,
possibly due to small sample sizes. Recently, a study of hip shape
models (HSM) derived from statistical shape modeling of DXA
scans found eight loci associated with hip shape28.
Here, we report a large GWA study of bone size using a simple
parameter from DXA scans, the bone area. We ﬁnd thirteen
independent associations of common variants at twelve loci that
replicate in population of European and East-Asian descent.
These are the ﬁrst genome wide signiﬁcant loci for DXA bone
area. We also investigate association of these variants with other
bone related traits and diseases (BMD, height, osteoarthritis, and
fractures), and ﬁnd all variants but one to associate with one of
these traits/diseases. We show that the relationship between DXA
bone area and these traits is, however, complex. We ﬁnd high
genetic correlation between femoral neck area and hip fracture,
and show that the DXA area measure contributes to the risk of
hip fracture independent of bone density. We demonstrate that a
variant in the microRNA MIR196A2 gene at the HOXC locus,
rs11614913, affects the efﬁciency ofMIR196A2 in repressing miR-
196a-5p target genes.
Results
Genome wide association study and replication. To search for
sequence variants that contribute to bone size we performed a
GWA study of bone area using DXA of the hip (total hip, and the
sub-regions femoral neck, trochanter, and intertrochanteric/shaft,
N ≥ 28,954) and of the lumbar spine (L1–L4, N= 29,059) (Sup-
plementary Fig. 1). We adjusted the bone area measurements for
sex, age, height and body mass index (BMI) and tested for
association between 33.4 million high quality sequence variants29
and the DXA bone areas (Methods).
Sixteen variants, all common, at 14 loci satisﬁed our criteria of
genome-wide signiﬁcance30 in the association analysis, and after
conditional analysis across the loci (Methods); eight for the
lumbar spine area, ﬁve for the total hip area, four for the
intertrochanteric area, three for the trochanter area, and one for
the femoral neck area (Table 1, Fig.1, Supplementary Fig. 2,
Supplementary Data 1 and 2, Supplementary Table 1). Two of the
hip area loci, at 17q24.3 near the SOX9 gene and at 4q31.21 near
the HHIP gene, have been reported to associate with hip shape28.
The SOX9 association is the same signal as reported for hip shape,
whereas rs12507427 near the HHIP gene represents an indepen-
dent signal at that locus.
We followed up these sixteen sequence variants in samples
with up to 21,277 subjects of European and East Asian descent
(Methods, Supplementary Table 2). All but three markers
replicated signiﬁcantly under a false discovery rate (FDR) of
0.05 (Table 1, Supplementary Data 3 and 4). The strongest
associations are rs11614913 in the microRNA gene MIR196A2
with reduced lumbar spine area (P= 2.3 × 10−42, β=−0.090),
rs143384 in the 5’UTR of GDF5 with increase in both total hip (P
= 2.2 × 10−22, β= 0.071) and trochanter area (P= 1.1 × 10−18, β
= 0.071), rs12601029 at 17q24.3 near the SOX9 gene with
increased intertrochanteric area (P= 6.2 × 10−18, β= 0.072), and
rs12507427 near HHIP for increase in femoral neck area (P=
8.4 × 10−14, β= 0.054).
We do not conﬁrm the previously reported suggestive
association with DXA hip area at the PLCL1 gene23 (P≥ 0.70),
or lumbar spine area at the HMGN3 gene25 (P≥ 0.56), whereas
our association of rs143384 in the 5’UTR of GDF5 with area of
both lumbar spine and hip is the same as the previous suggestive
association with lumbar spine area26 (r2= 0.78).
In addition to the SOX9 and HHIP loci, we ﬁnd association
between DXA hip area measures and ﬁve of the eight recently
reported hip shape loci28 under FDR of 0.05 (Supplementary
Data 5).
Functional annotation of variants and enrichment analysis. We
carried out functional annotation for the lead variants, along with
highly correlated variants (r2 > 0.8), using available data for active
chromatin marks in trait-relevant cells (Supplementary Data 6);
histone H3 mono-methylation and tri-methylation at lysine K4
(H3K4me1 and H3K4me3, respectively) and histone H3 acet-
ylation at lysine K27 (H3K27ac). This analysis identiﬁes ten DXA
area loci intersecting with H3K4me1 or H3K27ac marked regions
in primary osteoblasts, indicative of enhancers. The target genes
for these enhancers include SOX9, at 17q24.3 which is the key-
regulator of chondrocyte differentiation31, HHIP at 4q31.21
which encodes hedgehog interacting protein that is involved in an
important signaling pathway in osteoarthritis32, and COL11A1, a
ﬁbril forming collagen of the extracellular matrix (Supplementary
Data 6). Six loci are found in H3K4me3 regions of which ﬁve
localize proximal to a transcription start site, indicative of active
promoters (Supplementary Data 6).
Enrichment analysis for gene functions using DEPICT high-
lights genes with predicted functions in ribonucleoprotein
complex binding, as well as those in LSM5 and LSM7
protein–protein interaction subnetwork, implicated in splicing
and mRNA decay in P-bodies33, for lumbar spine area and hip
trochanter area association results, respectively (Supplementary
Data 7). DEPICT identiﬁed signiﬁcant tissue enrichment (FDR <
0.05) for two out of the ﬁve DXA area phenotypes, i.e., for hip
total area and hip trochanter area association results, in both
cases involving cartilage tissue (Supplementary Data 8). Of note,
we ﬁnd chondrocytes and osteoblasts among the list of top ﬁfteen
enriched cell-types ranked according to nominal P values in ﬁve
and three of the ﬁve DXA phenotypes, respectively.
Overexpression of MIR196A2 in HEK293T cells. The strongest
spine area associated SNP, rs1161491, is located in the microRNA
MIR196A2 gene at the HOXC gene cluster of developmental
transcription factors. The T allele of rs11614913 introduces a
wobble bond to the primary miR-196a hairpin transcript (U to G
paring instead of C to G pairing) without affecting the seed
sequences of either the 5p or 3p strands of the miR-196a duplex,
and hence, the variant is not expected to inﬂuence recognition of
target gene mRNAs. However, the variant might affect the efﬁ-
ciency of miR-196-5p target gene suppression either by affecting
the thermodynamic stability34 or processing of the mature miR-
196-5p duplex35–37 (Supplementary Note 1, Supplementary
Fig. 3).
To test this we transfected HEK293T cells with MIR196A2
expression plasmids containing either the C or T alleles of
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rs11614913 and assessed, by RNA-sequencing, whether the
two MIR196A2 alleles displayed differential effect on mRNA
expression (Methods, see Supplementary Note 1 for detailed
description of this experiment and results). We ﬁrst deﬁned a set
of seventeen high conﬁdence miR-196a-5p direct target
genes based on conservation scores for predicted binding sites
in 3´UTRs of mRNA sequences using TargetScan v7.2 (Supple-
mentary Fig. 4). Based on gene ontology analysis these direct
target genes are highly overrepresented in anterior/posterior
pattern speciﬁcation (25-fold; P= 1.7 × 10−5), as well as in
skeletal system development (13-fold; P= 2.5 × 10−5) (Supple-
mentary Table 3). In the transfected HEK293T cells, 14 of the
miR-196a-5p direct target genes are expressed (Supplementar-
y Note 1). In response to overexpression of either alleles of
MIR196A2, these 14 direct target genes are signiﬁcantly down-
regulated compared to the rest of the MIR196A2 transfected
HEK293 expressome (P adjusted < 0.05) (Fig. 2, Supplementary
Figs. 5 and 6, Supplementary Table 4). Contrasting the effects of
the C and T alleles on suppression of the 14 target genes we
observe a subtle difference, with the C allele suppressing
more than the T allele (Fig. 2c, d). Permutation-based
hypothesis test demonstrates that this suppression bias across
the 14 target genes is statistically signiﬁcant (P value= 0.042)
(Supplementary Note 1), showing that the rs11614913[T] allele of
MIR196A2 is less effective in repressing miR-196a-5p target
genes. The subtle difference in the suppression of the target genes
between the two alleles of MIR196A2 is to be expected given that
the alleles are common with small effects on lumbar spine area
and fracture risk. When analyzing gene enrichment for the entire
set of repressed genes due to experimental induction of
MIR196A2 (C-allelles or T-alleles) expression, which represent
both primary and secondary targets of miR-196a-5p, we ﬁnd
embryonic skeletal system morphogenesis among the signiﬁcant
enrichment of 31 functional gene ontology terms, supporting the
relevance of MIR196A2 for bone morphology (Supplementary
Fig. 7).
One of the miR-196a-5p direct target genes is HOXC8, located
in the same locus as rs11614913 in MIR196A2. The HOXC gene
cluster of developmental transcription factors plays a critical role
in limb development38 and skeletal patterning39. In our adipose
tissue samples from 746 individuals we ﬁnd that the rs11614913
[C] allele correlates with 4.5% reduction in expression of the
HOXC8 gene (P= 5.9 × 10−9) (Supplementary Fig. 8), consistent
with the effect of rs11614913 on the direct target genes in the
MIR196A2 transfected HEK293T cells. We note that another
highly correlated variant (r2= 0.90), and potentially functional as
it is in the promoter region of the HOXC8 gene, rs371683123, also
correlates with reduced expression of the HOXC8 gene (Supple-
mentary Fig 8, Supplementary Table 5). It is possible that
rs371683123 and other correlated variants also contribute to cis
regulation of HOXC8 expression in addition to the effect of
rs11614913 on MIR196A2 function.
Table 1 GWS DXA bone area variants in the Icelandic discovery samples
Discovery samples Replication samples All sets combined
Area SNP (region) Closest Gene VA EA /
OA
Freq P Effect P Effect P Effect (95% CI) P het
LS rs11614913 (12q13.13) MIR196A2 in pre-mir T/C 47.8 1.5 × 10−23 −0.094 1.5 × 10−20 −0.086 2.3 × 10−42 −0.09 (−0.103,
−0.077)
5.4 × 10−1
rs143384 (20q11.22) GDF5 5’UTR G/A 37.0 9.9 × 10−17 0.080 3.5 × 10−7 0.047 4.4 × 10−21 0.063
(0.050, 0.076)
1.3 × 10−2
rs10917168 (1p36.12) WNT4 intergenic T/A 28.4 3.3 × 10−12 0.072 2.6 × 10−13 0.075 5.8 × 10−24 0.074
(0.059, 0.088)
8.4 × 10−1
rs143793852 (18q21.1) DYM intron C/
CA
43.4 5.6 × 10−11 0.062 1.1 × 10−3 0.036 1.2 × 10−12 0.051
(0.037, 0.065)
7.3 × 10−2
rs8036748 (15q25.2) ADAMTSL3 intron A/T 46.2 1.3 × 10−10 −0.060 7.8 × 10−5 −0.037 2.2 × 10−13 −0.049 (−0.061,
−0.036)
8.2 × 10−2
rs2585073 (15q25.2) SH3GL3 intron C/G 34.9 1.3 × 10−10 0.063 0.55 0.006 5.6 × 10−7 0.035
(0.021, 0.049)
4.7 × 10−5
rs9341808 (6q14.1) BCKDHB intron C/A 47.1 1.7 × 10−10 0.060 8.9 × 10−8 0.049 1.1 × 10−16 0.054
(0.042, 0.067)
4.0 × 10−1
rs72979233 (11q13.4) CHRDL2 downstream G/A 25.7 4.4 × 10−10 −0.067 9.8 × 10−4 −0.034 2.1 × 10−11 −0.05 (-0.064,
−0.035)
1.2 × 10−2
Hip rs143384 (20q11.22) GDF5 5’UTR G/A 37.0 4.2 × 10−18 0.085 1.0 × 10−6 0.054 2.2 × 10−22 0.071
(0.057, 0.086)
3.6 × 10−2
rs3753841 (1p21.1) COL11A1 p.P1284L G/A 39.1 1.0 × 10−17 0.083 1.4 × 10−5 0.048 1.3 × 10−20 0.068
(0.054, 0.082)
1.7 × 10−2
rs9830173 (3p14.3) ERC2 intron C/G 38.4 6.0 × 10−13 0.070 2.2 × 10−3 0.035 8.0 × 10−14 0.055 (0.041, 0.07) 2.0 × 10−2
rs1507462 (18q23) intergenic A/G 30.4 1.8 × 10−12 −0.073 1.5 × 10−3 −0.034 3.5 × 10−13 −0.054
(−0.069, −0.04)
8.9 × 10−3
rs72834687 (17q23.2) TBX4 intron A/G 24.2 1.7 × 10−10 −0.068 9.4 × 10−2 −0.021 2.6 × 10−9 −0.048 (−0.064,
−0.032)
4.3 × 10−3
Inter rs12601029 (17q24.3) SOX9 intergenic A/G 33.5 4.4 × 10−14 0.074 2.8 × 10−5 0.068 6.2 × 10−18 0.072
(0.056, 0.089)
7.5 × 10−1
rs1159421 (17q24.3) SOX9 intergenic T/C 44.7 1.6 × 10−13 -0.069 5.4 × 10−3 −0.051 4.6 × 10−15 −0.065 (−0.082,
−0.049)
3.8 × 10−1
rs3753841 (1p21.1) COL11A1 p.P1284L G/A 39.1 2.2 × 10−11 0.064 3.6 × 10−3 0.041 7.4 × 10−13 0.057
(0.041, 0.072)
1.8 × 10−1
rs9830173 (3p14.3) ERC2 intron C/G 38.4 7.9 × 10−11 0.062 3.0 × 10−2 0.032 3.2 × 10−11 0.053
(0.037, 0.069)
1.2 × 10−1
Troch rs143384 (20q11.22) GDF5 5’UTR G/A 37.0 6.7 × 10−18 0.083 2.6 × 10−3 0.043 1.1 × 10−18 0.071
(0.055, 0.086)
2.0 × 10−1
rs3753841 (1p21.1) COL11A1 p.P1284L G/A 39.1 8.8 × 10−11 0.062 5.7 × 10−8 0.077 4.0 × 10−17 0.067
(0.051, 0.082)
3.8 × 10−2
rs10783854 (12q14.1) CTDSP2 upstream T/C 35.6 5.6 × 10−10 −0.060 2.4 × 10−1 -0.019 3.1 × 10−9 −0.049 (−0.066,
−0.033)
3.0 × 10−2
FN rs12507427 (4q31.21) HHIP 5’UTR A/T 43.1 1.2 × 10−10 0.059 1.1 × 10−4 0.110 8.4 × 10−14 0.054 (−0.036,
−0.007)
3.9 × 10−1
Results are shown for the DXA area phenotypes that were GWS in the discovery analyses, results for all markers across all DXA phenotypes in the discovery samples are shown in Supplementary Data 1,
results for all markers across all DXA area phenotypes combined in Supplementary Data 4, and in the replication samples split by European and Asian descent in Supplementary Data 3. Conditional
analysis between the two variants in the SOX 9 gene is shown in Supplementary Table 1. Results are shown for the Icelandic discovery set, the replication sets combined, and all sets combined. Region
refers to chromosomal location. EA designate the effect allele and OA the other allele. Freq. is the frequency of the effect allele in the Icelandic samples. Gene refers to the nearest gene and VA (variant
annotation) to effect on transcript or protein. The estimated effects are expressed as standardized values (standard deviations above or below the population average) per copy of the SNP allele. P values
are two sided and derived from a likelihood ratio test (Methods). P het is heterogeneity p value and is derived from a likelihood ratio test (Methods)
LS lumbar spine, Hip total hip, Inter intertrochanteric/shaft, Troch trochanter, FN femoral neck
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Association with other bone related phenotypes. To determine
whether the DXA bone area variants affect other bone pheno-
types we examined association of the sixteen DXA area markers
from our discovery analysis with osteoarthritis (Ncases=
25,458–27,321) and vertebral (Ncases= 3293) and hip fractures
(Ncases= 10,178) in European samples by either direct geno-
typing or in-silico look-up (Methods, Supplementary Table 2),
and with height and BMD in public datasets (GIANT1 and
GEFOS13, respectively).
Eight of the sixteen DXA bone area variants associate
signiﬁcantly with hip or knee osteoarthritis after correcting for
FDR (0.05), four associate with hip fractures, six associate with
BMD and twelve associate with height (Tables 2, 3). Two of the
three variants that did not replicate signiﬁcantly associate with
height, at 15q25.2 and 12q14.1, and one, at 17q23.2, with hip
osteoarthritis.
The osteoarthritis associating variants include the known knee
osteoarthritis variant rs143384 in the GDF5 gene32,40 (P= 4.2 ×
10−23, OR= 0.91), and the known missense variant in the
COL11A1 gene32, rs3753841 (p.Pro1284Leu) that associates with
hip osteoarthritis (P= 1.2 × 10−11, OR= 0.92). Both variants
associate with increased area and increased height (Tables 1, 3).
Furthermore, we show that rs3753841[G] in COL11A1 protects
against hip dysplasia as shown by higher center-edge angle (β=
0.444, P= 3.4 × 10−4), a measure of joint structure and shape
related to dysplasia41 (Supplementary Data 9).
The MIR196A2 variant, rs11614913[T], that associates with
reduced lumbar spine area (P= 2.3 × 10−42, β=−0.090) also
associates with increased risk of hip fractures (P= 1.0 × 10−8 and
OR= 1.11) (Table 2, Fig. 3), while it does not associate with DXA
bone area measures of the hip (P ≥ 0.010) (Supplementary
Data 1). This is the ﬁrst sequence variant reported to associate
with hip fractures to our knowledge. Furthermore, it associates
with reduced lumbar spine BMD in the public GEFOS dataset13
(Table 3), and confers modest risk of vertebral fractures in our
study (P= 0.025, OR= 1.07) (Supplementary Table 6).
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Fig. 1 Manhattan plots of the genome-wide analysis of the DXA bone area measures. The P values (−log10) are plotted against their respective positions
on each chromosome. Results are shown for all variants with signiﬁcance level P < 0.001 and imputation information greater than 0.8. The red line denotes
the signiﬁcance level of intergenic variants, P≤ 7.9 × 10–10. a Lumbar spine area (L1–L4) (N= 29,059), (b) Total hip area (N= 28,900), (c) Femoral neck
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Twelve of the DXA bone area variants1 associate with height in
the public GIANT dataset under a false discovery rate (FDR) of
0.05 (Table 3). This is despite initially correcting the DXA bone
area measurements for height of the individual. Furthermore, of
the 697 reported height variants1, additional 24 associate with
DXA bone area measures after correcting for the number of
markers tested (P Bonferroni ≤ 7.2 × 10−5) (Supplementary
Table 7). Although this high proportion of the DXA bone area
variants associate with height we ﬁnd little overall correlation
between the effects of reported height1 variants and their effect on
DXA bone area measures in our data (r2 ≤ 0.037) (Supplementary
Fig. 9). This is likely because some of the alleles that associate
with decreased DXA bone area associate with decreased height,
while other associate with increased height (Table 3, Fig. 4).
Mendelian randomization did not indicate a causal relationship
between height and DXA bone area (Supplementary Table 8).
Six of the DXA bone area variants associate with BMD in the
public GEFOS data under a false discovery rate (FDR) of 0.05
(Table 3), and additional eight reported BMD variants13 associate
with DXA area measures after correcting for the number of
markers tested (P Bonferroni ≤ 0.00071) (Supplementary Table 7).
We also observe some inconsistency in direction of effect on area
and BMD (Table 3, Fig. 4), however, the overall correlation betw-
een the effects of reported BMD variants11,13,15 and their effect
on DXA bone area measures is positive for lumbar spine BMD
(r2= 0.21, P= 7.4 × 10−5), whereas it is negative for hip BMD
(femoral neck BMD) (r2= 0.18, P= 0.00029) (Supplementary
Fig. 10). Mendelian randomization conﬁrmed these
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associations (Supplementary Table 8). The negative correlation-
with hip BMD may reﬂect the periosteal expansion observed with
age42 that is not captured by age adjustments of the
measures used. Likewise, the positive correlation between lumbar
spine area and lumbar spine BMD may reﬂect vertebral
degenerative changes that are not captured by these
adjustments either. Differences in trabecular and cortical
compartments of the bones that are not accounted for
in the area or BMD measures may also explain these
relationships43.
Table 2 Association of DXA bone area variants with osteoarthritis and hip fractures
Hip osteoarthritis
(N= 21,458/601,367)
Knee osteoarthritis
(N= 27,321/552,683)
Hip fractures
(N= 10,178/703,740)
GWS Pheno SNP (region) EA /
OA
P OR P het P OR P het P OR P het
LS rs11614913 (12q13.13) T/C 0.45 0.99 0.014 0.021 1.02 0.18 1.0 × 10−8 1.11 0.034
LS/Hip /
Troch
rs143384 (20q11.22) G/A 0.99 1 0.36 4.2 × 10
−23
0.91 0.87 0.60 1.01 0.48
LS rs10917168 (1p36.12) T/A 4.4 × 10−3 0.97 0.61 0.098 1.02 0.66 0.14 1.03 0.22
LS rs143793852
(18q21.1)
C/CA 0.76 1.01 0.85 0.11 0.97 0.16 0.27 1.02 0.41
LS rs8036748 (15q25.2) A/T 0.25 1.01 0.84 0.063 1.02 0.66 1.2 × 10−2 1.05 0.69
LS rs2585073 (15q25.2) C/G 0.83 1 0.33 0.94 1 0.31 0.029 0.96 0.27
LS rs9341808 (6q14.1) C/A 0.044 0.98 0.64 0.091 0.98 0.61 0.17 1.02 0.17
LS rs72979233 (11q13.4) G/A 0.59 1.01 0.016 2.4 × 10−4 1.04 2.6 × 10−3 6.4 × 10−3 0.95 0.92
Hip/Inter/
Troch
rs3753841 (1p21.1) G/A 6.7 × 10
−13
0.92 0.95 0.75 1 0.81 6.5 × 10−3 1.05 0.62
Hip/Inter/
Troch
rs9830173 (3p14.3) C/G 0.086 0.98 0.17 0.24 0.99 0.97 0.17 1.03 0.33
Hip rs1507462 (18q23) A/G 0.69 0.99 0.83 1.2 × 10−3 0.97 0.43 0.61 1.01 0.061
Hip rs72834687
(17q23.2)
A/G 1.7 × 10−4 1.05 0.7 0.29 1.01 0.39 0.82 1 0.46
FN rs12507427
(4q31.21)
A/T 0.46 0.99 0.077 0.79 1 0.29 0.13 1.03 0.73
Inter rs12601029
(17q24.3)
A/G 0.55 0.99 0.7 1.3 × 10−5 0.96 0.064 0.16 1.03 0.98
Inter rs1159421 (17q24.3) T/C 0.33 1.01 0.96 2.8 × 10−5 1.04 0.6 0.16 0.95 0.81
Troch rs10783854 (12q14.1) T/C 0.78 1 0.27 0.94 1 0.32 0.52 0.99 0.93
Results are shown for all sample-sets combined. GWS Pheno refers to the DXA bone area phenotype that was GWS in the discovery analyses. Region refers to chromosomal location. EA designate the
effect allele and OA the other allele. N is the number of individuals in the analyses: cases/controls. P het is the heterogeneity P value and OR is odds ratio. P values in bold are signiﬁcant for the phenotype
under FDR of 0.05. P values are two sided and derived from likelihood ratio test (logistic regression)
LS lumbar spine, Hip total hip, Troch trochanter, Inter intertrochanteric/shaft, FN femoral neck
Table 3 Association of DXA bone area markers with height and BMD
Height1 LS_BMD13 FN_BMD13
GWS Pheno SNP (region) EA/OA P value Effect P value effect P value Effect
LS rs11614913 (12q13.13) T/C 0.72 0.001 2.5 × 10−11 −0.059 5.8 × 10−7 −0.038
LS/Hip/Troch rs143384 (20q11.22) G/A 5.5 × 10−120 0.08 8.4 × 10−3 0.024 0.2 0.01
LS rs10917168 (1p36.12) T/A 5.7 × 10−7 0.02 2.6 × 10−4 −0.038 8.7 × 10−3 −0.024
LS rs143793852 (18q21.1) C/CA 1.7 × 10−35 0.04 0.56 0.005 0.75 0.002
LS rs8036748 (15q25.2) A/T 3.2 × 10−53 0.048 0.12 −0.015 0.016 0.02
LS rs2585073 (15q25.2) C/G 4.5 × 10−31 −0.039 0.25 0.011 0.09 −0.014
LS rs9341808 (6q14.1) C/A 3.7 × 10−4 0.026 0.87 −0.001 1 0
LS rs72979233 (11q13.4) G/A 5.7 × 10−4 −0.012 1.6 × 10−3 −0.033 0.71 −0.003
Hip/Inter/Troch rs3753841 (1p21.1) G/A 3.1 × 10−8 0.018 0.42 −0.007 0.061 −0.014
Hip/Inter/Troch rs9830173 (3p14.3) C/G 0.10 −0.005 0.96 −0.001 0.89 −0.024
Hip rs1507462 (18q23) A/G 0.39 −0.003 0.15 0.014 0.14 0.012
Hip rs72834687 (17q23.2) A/G 0.51 0.002 0.61 0.006 0.024 0.021
FN rs12507427 (4q31.21) A/T 4.9 × 10−63 0.053 0.41 0.007 0.24 −0.009
Inter rs12601029 (17q24.3) A/G 3.6 × 10−6 −0.015 0.97 0 2.3 × 10−3 −0.025
Inter rs1159421 (17q24.3) T/C 9.9 × 10−5 0.012 0.46 0.007 4.5 × 10−6 0.035
Troch rs10783854 (12q14.1) T/C 5.5 × 10−10 −0.025 0.64 −0.005 0.51 0.006
Results are shown for height in the GIANT dataset1 excluding the Icelandic samples, and the GEOFS dataset13, that did not include the Icelandic samples, for lumbar spine (LS) and femoral neck (FN)
bone mineral density (BMD). GWS Pheno refers to the DXA area phenotype that was GWS in the discovery analyses. Region refers to chromosomal location. EA designate the effect allele and OA the
other allele. The estimated effects are expressed as standardized values (standard deviations above or below the population average) per copy of the SNP allele. P values in bold are signiﬁcant for the
phenotype under FDR of 0.05
LS lumbar spine, Hip total-hip, Troch trochanter, Inter intertrochanteric/shaft, FN femoral neck
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Genetic correlation between DXA area and related phenotypes.
We examined the genetic correlation between the bone related
traits and DXA bone area by cross trait LD score regression44
across the Icelandic discovery set and the UK Biobank dataset
(Table 4, Supplementary Table 9).
Consistent with the lack of correlation between the effect
of variants on height and DXA bone area we ﬁnd little genetic
correlation between DXA bone area and height (rg= 0.064
for lumbar spine, and rg= 0.14 for hip). Likewise, we ﬁnd
consistent positive genetic correlation between DXA lumbar spine
area and BMD (rg= 0.30), and negative for hip BMD and hip
area (rg=−0.15).
For knee osteoarthritis there is no genetic correlation with any
of the area measures (rg ≤ 0.034), whereas there is a weak positive
correlation between hip area and hip osteoarthritis (rg=
0.11–0.18) but none for lumbar spine area and hip osteoarthritis
(rg= 0.043). The eight DXA bone area variants that associate
with knee or hip osteoarthritis are both lumbar spine (3) and hip
area (6) variants.
Hip fractures are substantially correlated genetically with the
femoral neck area (rg= 0.76), and even slightly more so than with
femoral neck BMD in our data (rg=−0.57). Recently, a large
meta-analysis of fractures showed high genetic correlation
between fracture and BMD (rg=−0.59), and that BMD has a
major causal effect on fracture45. Using multivariate logistic
regression, we cannot differentiate between contribution through
hip BMD, BMC, and the area measure on hip fractures, as each
trait showed independent association with hip fractures while
UK Biobank
Odds ratio 95% CI P value Cases Controls
1.22 (1.13, 1.32) 2.0 × 10–7 1788 405,154
1.08 (1.04, 1.12) 2.9 × 10–4 8068 296,532
1.05 (0.85, 1.31) 0.65 193 1538
1.16 (0.87, 1.56) 0.31 129 516
1.11 (1.07, 1.15) 1.0 × 10–8 10,178 703,740
Iceland
Denmark
Australia
Overall
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1.4
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Fig. 3 Forest plot showing estimated effect of rs11614913[T] in MIR196A2 on hip fractures. The odds ratio, 95% conﬁdence interval (CI), P value of
association and number of cases and controls is shown for each study. Source data are provided as a Source Data ﬁle
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Fig. 4 Effect on DXA bone area measures, height and bone mineral density. The effect on area measures are plotted on the X-axis and the effect on
reported height variants from the GIANT consortium1, and reported femoral neck BMD (FN_BMD) and lumbar spine BMD (LS_BMD) variants from the
GEFOS consortium13 are plotted on the Y-axis. Effects are in in standard deviations. The color of the dots/triangles/squares indicate the site of the DXA
area measure, and the shape indicates the strength of association with height, and hip and lumbar spine BMD; squares, non-signiﬁcant, dots, signiﬁcant
after correcting for FDR, and triangles, genome wide signiﬁcant. Source data are provided as a Source Data ﬁle
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09860-0 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2054 | https://doi.org/10.1038/s41467-019-09860-0 |www.nature.com/naturecommunications 7
adjusting for the other phenotypes (Table 5, Supplementary
Table 10, Supplementary Note 2). This indicates that all three
measures, area, BMD and BMC, inﬂuence the risk of hip fracture.
Of note is that lumbar spine area is associated with hip fractures
while adjusting for all the other traits (P= 0.0056), while lumbar
spine BMD is not signiﬁcant (P= 0.15).
Discussion
We have found thirteen sequence variants that associate with
simple measures of bone size; area measures from bone density
DXA scans. The scans assess the area (cm2) and the bone mineral
content (g) of the bone to produce the BMD (g/cm2), which is
used in evaluation of osteoporosis and risk of fractures. We are
here using a component of these commonly performed scans that
has not been extensively utilized in GWA studies as the BMD has.
Our study is the ﬁrst to report GWS associations to this trait. By
using this simple measure, we also ﬁnd association with pre-
viously reported hip shape loci, derived from statistical modeling
of the DXA images28. Hence, the DXA bone area associations are
likely to capture differences not only in the size of the bones, but
also, at least partly, in their shape.
Importantly, we found strong association of two of these DXA
bone area variants with osteoarthritis and one with hip fractures,
the ﬁrst signiﬁcant hip fracture locus reported to our knowledge.
These ﬁndings are in line with the idea that the size and shape of
bones inﬂuence their strength, and previous speculations that
they would inﬂuence the tendency to develop osteoarthritis. We
also show that the DXA bone area measure, as well as the BMC
measure of the DXA scans, are additional risk factors for hip
fracture independent of BMD. The BMD has recently been shown
to have a major causal effect on fractures45. Hence, all three
measures (BMD, BMC, and area) inﬂuence the risk of hip frac-
ture. The high genetic correlation that we ﬁnd between the
femoral neck area and hip fractures, which occur mostly at the
femoral neck, also reﬂects the inﬂuence of DXA bone area
measure on hip fracture. Interestingly, the lumbar spine area also
contributes to the risk of hip fractures, independent of BMD and
area of the hip. The association of the MIR196A2 variant with
lumbar spine area and hip fractures, but not hip area reﬂects this.
Despite the little genetic correlation between the DXA bone
area measures and height, most of these DXA area variants also
associate with height, although with inconsistent direction of
effects. We have recently demonstrated comparable relationship
between osteoarthritis and height, with the osteoarthritis risk
alleles associating either with increased or decreased height32,
resulting in little genetic correlation and little overall correlation
between the effects of variants on these two traits, similar to what
we report here for height and DXA bone area. These results
underscore the complex nature of bone longitudinal and radial
growth, mineralization, modeling and remodeling43. The complex
association pattern of the DXA area variants with height, BMD,
osteoarthritis and fractures may reﬂect different aspects of bone
biology, such as differences between longitudinal and radial
growth, or between trabecular and cortical compartments of the
bones, the mineralization process, modeling and remodeling, and
the periosteal expansion observed with age.
Finally, we show through overexpression in HEK293T cell line
that the variant in MIR196A2, that associates with both decreased
lumbar spine area and increased risk of hip fracture, directly
inﬂuences repression of miR-196a-5p target genes, with the
fracture associating allele, rs11614913[T], being less effective than
Table 4 Estimated genetic correlation
Combineda
Iceland UK Biobank rg s.e. P value rg 95% CI P value
LS area Height 0.056 0.038 0.15 0.064 −0.008, 0.14 0.082
Height LS area 0.16 0.13 0.22
Hip FN area Height 0.14 0.045 2.7E−03
LS area LS BMD 0.35 0.10 9.0E−04 0.30 0.13, 0.46 4.8E−04
LS BMD LS area 0.20 0.15 0.17
Hip FN area Hip FN BMD −0.15 0.16 0.36
LS area Knee OA −0.040 0.059 0.50 −0.034 −0.15, 0.078 0.55
Knee OA LS area 0.089 0.26 0.74
Hip FN area Knee OA −0.026 0.075 0.73
LS area Hip OA 0.076 0.077 0.32 0.043 −0.10, 0.19 0.55
Hip OA LS area −0.28 0.24 0.25
Hip FN area Hip OA 0.11 0.086 0.19
Hip fracture FN BMD −0.59 0.24 0.014 −0.57 −0.86, −0.28 9.8E−05
FN BMD Hip fracture −0.56 0.19 2.5E−03
Hip FN area Hip fracture 0.76 0.28 6.6E−03
We estimated the genetic correlation between the traits using cross-trait LD score regression44 on the GWAS summary statistics from Iceland and UK Biobank. rg is the genetic correlation coefﬁcient, s.
e. is standard error, and CI conﬁdence interval. Effect estimates obtained using weighted linear regression with s.e. and P values estimated with a block jackknife method44. Hip area measures are not
available in the UK Biobank dataset limiting the analysis to hip area in Iceland versus the other phenotypes in the UK Biobank, and not vice versa. Full results are shown in Supplementary Table 8.
LS lumbar spine, FN femoral neck, OA osteoarthritis, BMD bone mineral density. a Combined values do not include data from 'Hip FN area' rows
Table 5 Contribution of DXA bone area, BMC and BMD to
the risk of hip fractures
Phenotype OR 95% CI P value
LS_Area 0.97 0.95, 0.99 0.0045
LS_BMC 1.06 1.01, 1.11 0.020
LS_BMD 0.97 0.93, 1.01 0.12
Hip_Area 1.14 1.10, 1.17 6.6E−16
Hip_BMC 0.79 0.74, 0.84 1.7E−14
Hip_BMD 1.18 1.12, 1.24 1.3E−09
We estimated the contribution of the different DXA measures on the risk of hip fractures by
multivariate logistic regression. The P values are two-sided and were derived by likelihood ratio
test, adjusting for all the other phenotypes. Source data are provided as a Source Data ﬁle
LS lumbar spine, BMC bone mineral content, BMD bone mineral density, CI conﬁdence interval,
OR odds ratio
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the rs11614913[C] allele. Many of the miR-196a-5p target genes
play roles in development of the skeletal system, such as HOXC8,
located within the HOXC gene cluster proximal to MIR196A2,
underscoring the biological relevance of miR-196a-5p to bone
morphology. Together these data warrants further studies in bone
relevant cells.
Methods
Iceland discovery population. The Icelandic samples with area measurements
have previously been described in detail15. The area measures are derived from
densitometers at the Landspitali University Hospital’s DXA clinic and the Research
Service Center’s Heilsurannsokn DXA clinic, both using Hologic DXA machines.
Values at the hip (total hip, intertrochanteric, trochanteric and femoral neck) and
at lumbar spine (L1-L4) were corrected for machine, and adjusted for age, height
and body mass index and standardized in each gender separately to have a mean=
0 and standard deviation= 1.
Information on osteoarthritis (OA) were derived from a national Icelandic hip
or knee arthroplasty registry and from Landspitali University Hospital electronic
health records. Fracture assessment was through Landspitali University Hospital’s
electronic health records from 1999 to 2016, excluding high trauma fractures
according to the NOMESCO Classiﬁcation of External Causes of Injuries or based
on a detailed questionnaire. We only included patients who were 40 years or older
at the time of joint replacements and vertebral fractures, and older than 50 years at
the time of a hip fracture.
All participants who donated samples gave informed consent and the National
Bioethics Committee of Iceland approved the study (VSN-15-198) which was
conducted in agreement with conditions issued by the Data Protection Authority of
Iceland. Personal identities of the participant’s data and biological samples were
encrypted by a third-party system (Identity Protection System), approved and
monitored by the Data Protection Authority.
Replication populations. The Danish samples are postmenopausal women in the
age range 55–86 years, taking part in the Prospective Epidemiological Risk Factor
(PERF study)46. Area measures are from DXA-measurement (Hologic QDR2000)
at the hip (total hip, femoral neck and intertrochanteric) and lumbar spine.
Osteoporotic fractures included self-reported low trauma fractures and vertebral
fractures assessed by digital measurements of morphologic changes. Hip and knee
joint replacements and OA information were derived from the Land-
spatientregistret, 1996–2014. The study was approved by the Ethical Committee of
Copenhagen County and was in accordance with the principles of the Helsinki.
The Swedish samples were from the Swedish Malmo Diet and Cancer (MDC)
study of men and women living in the city of Malmo in Sweden who were born
between 1923 and 1945 (men) or between 1923 and 1950 (women). The inclusion
examination was performed during 1991–1996. The participants (n= 28,449) were
followed until ﬁrst OA surgery, emigration from Sweden, or death until December
31 2005. Information on knee and hip arthroplasty for OA and mortality were
from the national Swedish Hospital Discharge Register and the Swedish Causes of
Death Register. Cases were deﬁned as those who were treated with knee or hip
arthroplasty (421 and 551, respectively) during the follow-up time. Controls
matched each arthroplasty case for age, gender and BMI. The MDC study was
approved by the research ethical committee at Lund University the MDC study
(LU 51–90). All participants signed a written informed consent.
The Australian samples were derived from the Dubbo Osteoporosis
Epidemiology Study (DOES)47, including subjects in the age range 60–99 years. All
are of Caucasian ethnicity. Area was measured at the lumbar spine and the hip
femoral neck by DXA (LUNAR DPX-L) and corrected for gender, age, height and
weight. Osteoporotic fractures included low trauma fractures assessed by
questionnaire and ascertained by reviewing all radiography reports. The St.
Vincent’s Ethics Review Committee (Sydney) approved the study, and all subjects
gave written informed consent.
The Dutch samples are from the Rotterdam study, an ongoing population-
based prospective cohort comprising 14,926 Dutch individuals aged 45 years and
older48. After its initiation in 1990 (RSI, N= 7983) the cohort had two follow up
waves in 2000 (RSII, N= 3011) and 2006 (RSIII, N= 3932). Follow-up
examinations were scheduled every 3–5 years. The Rotterdam Study was approved
by the Medical Ethics Committee of the Erasmus MC and by the Ministry of
Health, Welfare, and Sport of the Netherlands, implementing the Wet
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All
participants provided written informed consent to participate in the study and to
obtain information from their treating physicians. DXA measurements in RSI-4
(2002–2004) and RSIII-1 (2006–2008) were done using Ge-Lunar Prodigy bone
densitometer while in RSII-3 (2011–2012) aBMD was measured using iDXA total
body fan-beam densitometer. The DXA area measures were adjusted for age, sex,
and ﬁrst 4 genetic principal components, and corrected for genomic control. The
OA deﬁnition and related structural phenotypes were deﬁned based on radiographs
of the hip, hand and knee joints. We have used the following radiographic
measurements to create (semi)-quantitative endophenotypes for the hip, knee,
hand, ﬁnger and thumb joints: JSN (0–3 scoring), JSW (mm), Osteophytes
(0–3 scoring), and Kellgren-Lawrence(KL)-score (0–5). Using these measurements
we have deﬁned the following structural OA phenotypes: Finger/Hand/Thumb/
Knee/Hip JSN sum score, osteophyte sum score, KL sum score and Hip JSW. In
addition, based on clustering of the data, we made an additional subdivision of the
Knee joint in lateral and medial side (JSN medial/lateral and Osteophyte score
medial/Lateral), and divided the hip joint into the acetabulum and femoral head.
Joint space width (JSW) was assessed at pelvic radiographs in anteriorposterior
position andmeasured in mm, along a radius from the center of the femoral head.
Within the Rotterdam Study, a 0.5 mm graduated magnifying glass laid directly
over the radiograph was used to measure the joint space width of the hip joints.
Acetabular dysplasia was measured using the Center-Edge angle or also known as
the Wiberg (CE-angle). The angle was measured using statistical shape model
(SSM) software. A continuous phenotype was used for the CE-angle, because of the
normal distribution of the measured angles. Since the CE-angle of the right hip and
the left hip has a high correlation (Pearson correlation coefﬁcient 0.68), only the
CE-angle of the right hip was used in our GWAS.
There are two studies from the United Kingdom; The UK Biobank sample-set
(http://www.ukbiobank.ac.uk) and the Arthritis Research UK Osteoarthritis
Genetics (arcOGEN, http://www.arcogen.org.uk)/United Kingdom Household
Longitudinal Study (UKHLS) analyses (https://www.understandingsociety.ac.uk).
arcOGEN is a collection of unrelated, UK-based individuals of European ancestry
with knee and/or hip osteoarthritis (OA) from the arcOGEN Consortium49. Cases
were ascertained based on clinical evidence of disease to a level requiring joint
replacement or radiographic evidence of disease (Kellgren–Lawrence grade ≥ 2).
The arcOGEN study was ethically approved by appropriate review committees, and
the prospective collections were approved by the National Research Ethics Service
in the United Kingdom. All subjects in this study provided written, informed
consent. The United Kingdom Household Longitudinal Study, also known as
Understanding Society, is a longitudinal panel survey of 40,000 UK households
(England, Scotland, Wales and Northern Ireland) representative of the UK
population. Since 2009 participants are surveyed annually and contribute
information relating to their socioeconomic circumstances, attitudes, and behavior
via a computer assisted interview. The study includes phenotypical data for a
representative sample of participants for a wide range of social and economic
indicators and biological sample collection including biometric, physiological,
biochemical, and hematological measurements, as well as self-reported medical
history and medication use. The United Kingdom Household Longitudinal Study
has been approved by the University of Essex Ethics Committee and informed
consent was obtained from every participant.
The UK Biobank study is a large prospective cohort study of ~500,000
individuals from across the United Kingdom, aged between 40–69 at recruitment50.
DXA area measures were only available for the lumbar spine, for 5075 individuals.
The measures were adjusted for age, height and body mass index in each sex
separately and standardized to a mean= 0 and standard deviation= 1.
Osteoarthritis at the hip and knee was deﬁned as total hip or knee replacement
after the age of 40 years and ICD10 codes indicating osteoarthritis. Femoral neck
fractures comprised the hip fracture group and lumbar vertebrae fracture the
vertebral fractured group. We only included individuals of UK European descent.
UK Biobank’s scientiﬁc protocol and operational procedures were reviewed and
approved by the North West Research Ethics Committee (REC Reference Number:
06/MRE08/65), and informed consent was obtained from all participants. This
research has been conducted using the UK Biobank Resource under Application
Number 23359.
The Chinese Hong Kong samples are comprised of two samples of different sex,
the Mr OS and Ms OS studies, aged 65 years and above51. The DXA bone area
measures were derived using Hologic QDR-4500W densitometer and corrected for
gender, age, height, and weight. All participants provided informed consent. The
Clinical Research Ethics Committee of the Chinese University of Hong Kong
approved the study.
The Korean samples are postmenopausal women who visited the Osteoporosis
Clinic of Asan Medical Center (AMC, Seoul, Korea)52. Bone area was measured at
the femoral neck and the lumbar spine (L1-L4) using Lunar-Expert XL, and
Hologic-QDR 4500-A absorptiometers. The DXA area measures were corrected for
machine, gender, age, height and weight. All participants provided informed
consent. The AMC Ethics Review Committee (Seoul) approved the study.
The Vietnamese samples are from the Vietnam Osteoporosis Study (VOS), a
population study in Ho Chi Minh City to map genome and exposome factors for
predicting chronic diseases, including osteoporosis and fracture53. DXA bone area
data was derived using Hologic Horizon densitometer and corrected for gender,
age, height and weight. The study’s procedure and protocol were approved by the
research and ethics committee of the People’s Hospital 115 on August 6, 2015
(Approval number 297/BVNCKH).
All participants in these studies provided informed consent, and we obtained
approval from all institutional review board to carry out the study.
DXA area measures. Measurement of the different parameters is automated
within the DXA machine software. Each machine is calibrated every morning
before operation using a phantom. The two DXA machines used in Iceland were
further calibrated by measuring a group of the same individuals on both machines.
There are two main manufacturers of DXA machines, Hologic (https://www.
hologic.com/hologic-products/breast-skeletal/horizon-dxa-system) and Lunar
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(https://www.gehealthcare.com/en/products/bone-health-and-metabolic-health),
each with their own software and means to optimize the results. All the measures
for the Icelandic discovery samples were done using Hologic machines whereas the
replication studies used either Hologic or the Lunar machines. There are some
differences between the two machines, which are difﬁcult to fully account for.
However, using standardized measures rather than absolute values from the
machines we believe most of those differences are accounted for in our analyses.
Supplementary Fig. 1 was borrowed from the manufacturer of the Hologic DXA
machines and illustrates the different areas measured. The Hologic manufacturers
refer to the intertrochanteric/shaft area as intertrochanteric, and the Lunar man-
ufacturers as shaft. This includes also the lesser trochanter. The femoral head is not
included in the output from the DXA machines.
Association analysis in the Icelandic samples. We sequenced the whole genomes
of 15,220 Icelanders using Illumina technology to a mean depth of at least 10 ×
(median 32 × )29,54. SNPs and indels were identiﬁed and their genotypes called
using joint calling with the Variant Effect Predictor (version 84)55. We improved
genotype calls were by using information about haplotype sharing, taking advan-
tage of the fact that all the sequenced individuals had also been chip-typed and long
range phased. We then imputed the 33.4 million variants that passed high quality
threshold into 151,677 Icelanders who had been genotyped with various Illumina
SNP chips and their genotypes phased using long-range phasing. Using genealogic
information, the sequence variants were imputed into un-typed relatives of the
chip-typed to further increase the sample size for association analysis and increased
the power to detect associations. All of the variants that were tested had imputation
information over 0.8.
Quantitative traits were tested using a linear mixed model implemented in
BOLT-LMM56. The area measures were corrected for age, height, and body mass
index in each sex separately prior to regression analysis. The case-control analysis
were done using logistic regression, adjusted for gender, age and county.
We applied the method of LD score regression57 to account for inﬂation in test
statistics due to cryptic relatedness and stratiﬁcation, We regressed the χ2 statistics
from our GWAS scan against LD score with a set of 1.1 M variants and used the
intercept as a correction factor. We downloaded the LD scores from a LD score
database (ftp://atguftp.mgh.harvard.edu/brendan/1k_eur_r2_hm3snps_se_weights.
RDS; Accessed 23 June 2015). For the quantitative traits reported here, the
estimated inﬂation factors based on LD score regression were 0.93 for the total hip
area, 0.94 for the femoral neck area, 0.92 for the intertrochanteric area, 0.92 for the
trochanteric area, and 0.93 for the lumbar spine area. For the case control analysis,
the estimated inﬂation factors were 1.40 for hip osteoarthritis, 1.33 for knee
osteoarthritis, 1.18 for hip fractures, and 1.07 for vertebral fractures.
We used the weighted Holm–Bonferroni method to allocate familywise error
rate of 0.05 equally between ﬁve annotation-based classes of sequence variants30.
This yielded signiﬁcance thresholds of 2.6 × 10−7 for high-impact variants
(including stop-gained and loss, frameshift, splice acceptor or donor and initiator
codon variants; N= 8474), 5.1 × 10−8 for missense, splice-region variants and in-
frame-indels (N= 149,983), 4.6 × 10−9 for low-impact variants (including
synonymous, 3′ and 5′ UTR, and upstream and downstream variants, N=
2,283,889), 2.3 × 10−9 for deep intronic and intergenic variants in DNase I
hypersensitivity sites (DHS) (N= 3,913,058) and 7.9 × 10−10 for other non-DHS
deep intronic and intergenic variants (N= 26,108,039).
Genotyping of replication samples. The samples from Denmark, Sweden, Aus-
tralia, Hong Kong, Korea and Vietnam were directly genotyped on the Centaurus
(Nanogen) single-SNP genotyping platform.
The Rotterdam Study cohorts (RS-I, RS-II, and RS-III) were genotyped using
commercially available genotyping arrays, and genotyping quality control (QC)
was done separately for each. The genome-wide arrays were used to impute
variants with HRC58. The imputation was preformed using the Michigan
Imputation server59. The server uses SHAPEIT2(v2.r790) to phase the data and
Minimac 3 for imputation to the HRC reference panel (v1.0). Prior imputation the
genotypes were ﬁltered using scripts provided online (HRC Imputation preparation
and checking: http://www.well.ox.ac.uk/~wrayner/tools/; 4.2.5). GWAS were
carried out under an additive model in RV-test using HRC v1.0 imputations, with
adjustment for age, sex and the ﬁrst 4 principle components. EasyQC was used to
conduct quality control across cohorts (excluded: MAF < 0.05). Cleaned results
were combined in a joint meta-analysis (METAL: inverse variance weighing).
A total of 7410 arcOGEN cases were genotyped on the Illumina Human 610-
Quad array, 670 arcOGEN cases were genotyped on the Illumina OmniExpress
array, and 9296 United Kingdom Household Longitudinal Study (UKHLS)
controls were genotyped on the Illumina CoreExome array. Prior to imputation all
variants were mapped to GRCh37 and cases and controls were merged into a single
dataset containing only those variants overlapping between the 3 datasets.
Additional variants were excluded if they had a minor allele frequency (MAF) ≤ 1,
were indels, were differentially missing between cases and controls (Fisher’s exact
test p < 0.0001). In addition, we performed a case-control analysis and visually
inspected the cluster plots for any variant with p ≤ 5 × 10−8. Final quality control
checks prior to imputation were performed using a HRC pre-imputation checking
tool. Imputation was performed on 17,376 individuals and 126,188 variants using
the Michigan HRC imputation58,59 server with Eagle260 for the prephasing. Post
HRC-imputation we excluded related individuals by performing multi-dimensional
scaling and identity by descent (using PI_HAT threshold > 0.2) in PLINK61 using
the directly typed variants. We performed association analysis using SNPtest62 and
we included the ﬁrst ten principal components as covariates. There were 3312 total
hip joint replacement cases and 2,421 total knee joint replacement cases and 9268
controls with 7,648,357 and 7,647,669 variants with an imputation information
score > 0.3 and MAF > 1% for the hip and knee analysis, respectively.
The UK Biobank samples were genotyped was performed using a custom-made
Afﬁmetrix chip, UK BiLEVE Axiom63, in the ﬁrst 50,000 participants, and with
Afﬁmetrix UK Biobank Axiom array in the remaining participants;64 95% of the
signals are on both chips. Wellcome Trust Centre for Human Genetics performed
Iimputation by using a combination of 1000 Genomes phase 3, UK10K, and HRC
reference panel reference panels in two steps; The HRC panel was used as ﬁrst
choice option, but for SNPs not in that reference panel the UK10K+ 1000
Genomes panel was used65. We only used markers imputed based on the HRC
panel due to problems in the UK10K+ 1000 Genomes panel imputation for
this study.
Meta-analyses. Results from the Icelandic discovery results and replication
datasets were combined using an inverse-variance weighted meta-analysis, where
different datasets we allowed to have different populations frequency for alleles and
genotypes but assumed to have a common effect (ﬁxed effect). Heterogeneity in the
effect estimates was tested using a likelihood ratio test by comparing the null
hypothesis of the effect being the same in both populations to the alternative
hypothesis of either population having a different effect.
Genetic correlations. We used the cross-trait LD score regression method44 and
the summary statistics from the Icelandic and UK Biobank datasets for estimation
of genetic correlation between pairs of traits. We used results for about 1.2 million
variants, well imputed in both datasets, in this analysis, and for LD information, we
used pre-computed LD scores for European populations (downloaded from https://
data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2). We calcu-
lated the genetic correlation between Icelandic GWAS summary statistic for one
trait and the UK GWAS summary statistic for the other traits, and the vice versa,
and then meta-analyzed those results to avoid bias due to overlapping samples.
Area measures for the hip were not available for the UK Biobank dataset.
Mendelian randomization. Causal relationships between DXA bone area and
height and BMD were estimated with a two sample Mendelian Randomization,
using GIANT and GEFOS effect estimates for height and BMD, respectively, as
instrumental variables. The Mendelian randomization was performed with the
MendelianRandomization package in R66.
Functional annotation of DXA bone area associated variants. For each lead
variant we identiﬁed variants in linkage disequilibrium (LD) on the basis of in-
house genotype data to the nearest 100,000 variants (r2 > 0.8) to deﬁne an LD class.
We then annotated these variants by intersection with chromatin immunopreci-
pitation (ChIP) signal data and Dnase hypersensitivity data for osteoblasts primary
cells. The ChIP-seq data was derived from the ENCODE project67 and downloaded
in pre-processed (MACS v2 algorithm) bigWig format, representing analysis of
acetylated histone H3 at lysine K27 (H3K27ac) marks with accession number
ENCFF380JNO. To account for multiple hypothesis the signal P-values were
adjusted by the Benjamini–Hochberg procedure and thresholded at the 1% FDR
signiﬁcance level. DNase hypersensitivity data (DHS) for osteoblasts was also
downloaded in pre-processed narrow peak format (accession number
ENCFF510LHV), and intersected with variant position in each LD class. Super-
enhancer proﬁle for osteoblast cells, based on H3K27ac data derived from the
Encode project (GSM733739), was derived from Hnisz et. al.68 Similar data for
chondrocytes data was not available.
To identify enhancer targets genes, we made use of the Joint effect of multiple
enhancers (JEME) resource69. Additionally, we used Genhancer elite predictions
which is based on multiple data types (eQTLs, C-HiC, TF co-expression and eRNA
co-expression, and distance) where the presence of at least two different types of
data point to enhancer-gene targets. We permit all predictions in the elite version
other than those where distance underlies the prediction, i.e., where distance is one
of only two evidence levels. DEPICT analysis70 was carried out using association
variants with nominal P-value < 1e−5, separately for each of the ﬁve phenotypes.
MIR196 experiments. The full length mir196A2 cDNA (RefSeq: MI0000279) in
pCMV-MIR mammalian expression vector was obtained from Origene in addition
to an empty pCMV-MIR vector (product ID: pCMVMIR). Transformed TOP10
chemically competent cells (ThermoFisher C404006) were plated on LB plates
containing 50 µg/ml kanamycin. Colonies were expanded in LB medium con-
taining 50 µg/ml kanamycin. Plasmids were puriﬁed using Plasmid maxi kit
(Qiagen 12163) following the manufacturer’s protocol, resulting in Mir196A2_WT
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and Mir_Empty plasmids. Sanger sequencing conﬁrmed the sequence of
Mir196A2_WT.
In order to create the Mir196A2 variant, we used the Q5 Site-directed
mutagenesis kit (New England BioLabs E0554S) and the pCMV-mir196A2_WT
plasmid was used as a template, with the following primers F-5′
CAAGAAACTGtCTGAGTTACATC ′3 and R-5′ TTGCCGAGTTCAAAACTC ′3.
Sanger sequencing conﬁrmed the sequence of Mir196A2_Mut.
Transfection experiments were independently done in six replicates for each
condition (n= 18). One day prior to transfection, 500.000 HEK293T cells (ATCC®
CRL-3216) were seeded into each well of a 6-well plate in 2 ml of Dulbecco’s
Modiﬁed Eagle Medium medium (ThermoFisher 31966021) supplemented with
10% fetal calf serum (ThermoFisher 10082147) and 50 units/ml penicillin and 50
µg/ml streptomycin (ThermoFisher 15070063). On the day of transfection,
medium was replaced with 3 ml of the identical media as before without antibiotics.
For each transfected well, 3.3 µg of Mir_Empty, Mir196A2_WT or Mir196A_Mut
plasmids were diluted in 155 µl Opti-Mem (ThermoFisher 31985047) and 9.9 µl
Fugene HD (Promega E2312). Incubated at room temperature for 10 min before
150 µl of transfection mix was added to the appropriate well.
Forty eight hours after transfection, cells were harvested for cell sorting. Cells
were released from the plate surface with TrypLE Express (ThermoFisher
12605010) and then washed with 2% FBS (ThermoFisher 10500064) in dPBS
(ThermoFisher 14190144). After washing, cells were diluted in 1 ml of 2% FBS in
dPBS with 1:1000 DAPI (Sigma D9542). Live cells were then positively sorted for
the expression of GFP using a Sony SH800S cell sorter, giving a purity of >85%
transfected cells.
Cells were ﬁrst gated by size with FSC Area/SSC Area and doublets were
excluded by gating at FSC Height/FSC Area. Unstained cells were then used to
specify the gating for negative cells. DAPI stained cells were also used to deﬁne the
live/dead gate (Supplementary Fig. 11).
RNA from sorted cells was isolated using RNeasy plus mini kit (Qiagen 74136)
following the manufacturer’s protocol. After isolation, RNAsecure (ThermoFisher
AM7006) was added to the RNA and samples heated for 10 min at 60 °C. Samples
cooled down on ice and then placed in −80 °C.
The quality and quantity of total RNA samples were assessed and analyzed
using the Total RNA 6000 Nano Chip for the Agilent 2100 Bioanalyser. TruSeq v2
RNA Sample Prep Kit (Illumina) was used to generate cDNA libraries derived from
Poly-A mRNA. In brief, Poly-A mRNA from total RNA samples (0.5–1 μg input)
was captured by hybridization to Poly-T beads. This was followed by fragmentation
at 94 °C of the Poly-A mRNA, and ﬁrst-strand cDNA prepared using SuperScript II
Reverse Transcriptase (Invitrogen) and random hexamers, followed by second-
strand cDNA synthesis, end repair, addition of a single A base, indexed adapter
ligation, AMPure bead puriﬁcation and PCR ampliﬁcation. Bioanalyser was used to
measure the resulting cDNA sequencing libraries using DNA 1000 Lab Chip.
Sequencing was then carried out on a HiSeq2500 sequencer, with four indexed
samples per lane. RTA (real-time analysis) and bcl2fastq software packages
(Illumina), were used to generate basecalls and Fastq ﬁles, respectively. RNA
transcript expression was then quantiﬁed with Kallisto71 using cDNA sequences of
the Ensembl v87 reference transcriptome72. Gene expression estimates were
computed by aggregating transcript expression using tximport73 R package. The
gene expression difference in a pairwise comparison of groups; rs11614913[T],
rs11614913[C] and empty was compared using DESeq2 R package74. Low
expressed genes were excluded from the analysis if the average expression was
below ﬁve fragments counts. P-values were corrected for multiple hypothesis
testing using the Benjamini and Hochberg method.
RNA sequencing and correlation in adipose tissue. RNA sequencing analysis
was performed on subcutaneous adipose tissue samples obtained from 749 Ice-
landers. RNA sequencing was as described above for the MIR196A2 experiment.
Association between variant and gene expression was estimated using a generalized
linear regression, assuming additive genetic effect and log-transformed gene
expression estimates, adjusting for measurements of sequencing artefacts, demo-
graphy variables, and hidden covariates75.
URLs. For the arcOGEN Study, see http://www.arcogen.org.uk/; for the UK Bio-
bank, see http://www.ukbiobank.ac.uk/; for the United Kingdom Household
Longitudinal Study, see https://www.understandingsociety.ac.uk; for HRC pre-
imputation checking tool, see http://www.well.ox.ac.uk/~wrayner/tools/#Checking;
for rre-computed LD scores for European populations, see https://data.
broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2); for Hologic DXA
machines, see https://www.hologic.com/hologic-products/breast-skeletal/horizon-
dxa-system, and for Lunar DX machines, see https://www.gehealthcare.com/en/
products/bone-health-and-metabolic-health.
Data availability
The Icelandic population WGS data has been deposited at the European Variant Archive
under accession code PRJEB15197, and the RNA sequencing results from the MIR196A2
experiments to Gene Expression Omnibus, accession code GSE128641. The GWAS
summary statistics are available at https://www.decode.com/summarydata. The authors
declare that the data supporting the ﬁndings of this study are available within the article,
its Supplementary Data ﬁles and upon request. A reporting summary for this Article is
available as a Supplementary Information ﬁle. The source data underlying Figs. 1–4 in
the main text, and for Supplementary Figs. 2, 4, 5, 6, 8, 9, 10, and for Table 5, are
provided as Source Data ﬁles.
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